These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 28216367)

  • 1. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL
    Kumar V; Shin JS; Shie JJ; Ku KB; Kim C; Go YY; Huang KF; Kim M; Liang PH
    Antiviral Res; 2017 May; 141():101-106. PubMed ID: 28216367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4--The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS).
    St John SE; Tomar S; Stauffer SR; Mesecar AD
    Bioorg Med Chem; 2015 Sep; 23(17):6036-48. PubMed ID: 26190463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational modeling of the bat HKU4 coronavirus 3CL
    Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
    J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
    Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
    Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
    Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors.
    Kumar V; Tan KP; Wang YM; Lin SW; Liang PH
    Bioorg Med Chem; 2016 Jul; 24(13):3035-3042. PubMed ID: 27240464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
    Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
    Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
    J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus.
    Cheng KW; Cheng SC; Chen WY; Lin MH; Chuang SJ; Cheng IH; Sun CY; Chou CY
    Antiviral Res; 2015 Mar; 115():9-16. PubMed ID: 25542975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad-spectrum coronavirus antiviral drug discovery.
    Totura AL; Bavari S
    Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
    Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
    Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.
    Galasiti Kankanamalage AC; Kim Y; Damalanka VC; Rathnayake AD; Fehr AR; Mehzabeen N; Battaile KP; Lovell S; Lushington GH; Perlman S; Chang KO; Groutas WC
    Eur J Med Chem; 2018 Apr; 150():334-346. PubMed ID: 29544147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling.
    Alvarez N; Adam GC; Howe JA; Sharma V; Zimmerman MD; Dolgov E; Rasheed R; Nizar F; Sahay K; Nelson AM; Park S; Zhou X; Burlein C; Fay JF; Iwamoto DV; Bahnck-Teets CM; Getty KL; Lin Goh S; Salhab I; Smith K; Boyce CW; Cabalu TD; Murgolo N; Fox NG; Mayhood TW; Shurtleff VW; Layton ME; Parish CA; McCauley JA; Olsen DB; Perlin DS
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.
    Kilianski A; Mielech AM; Deng X; Baker SC
    J Virol; 2013 Nov; 87(21):11955-62. PubMed ID: 23986593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.